Liu Jun

Dr. Liu Jun


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Nanomaterials
Verified
Journal Article
Open access
PDF file
KMKai Ma
Kai Ma
LYLuoxing Yang
Luoxing Yang
LJLiu Jun
Liu Jun
JLJiyang Liu
Jiyang Liu
Screen-printed carbon electrodes (SPCEs) bear great potential in the detection of biomarker in clinical samples with low sample consumption. However, modification of electrode surfaces to improve the anti-interference ability and sensitivity is highly desirable for direct electroanalysis of whole blood samples. Here, a reliable and miniaturized electrochemical sensor is demonstrated based on SPCE equipped with vertically-ordered mesoporous silica-nanochannel film (VMSF). To achieve stable binding of VMSF and improve the electrocatalytic performance, electrochemically reduced graphene oxide (ErGO) is applied as a conductive adhesion layer, that is in situ reduced from GO nanosheets during fast growth (less than 10 s) of amino groups modified VMSF (NH2-VMSF) using electrochemically assisted self-assembly (EASA). In comparison with bare SPCE, NH2-VMSF/ErGO/SPCE exhibits decreased oxidation potential of uric acid (UA) by 147 mV owing to significant electrocatalytic ability of ErGO. The dual signal amplification based on electrocatalysis of ErGO and enrichment of nanochannels leads to enhanced peak current by 3.9 times. Thus, the developed NH2-VMSF/ErGO/SPCE sensor enables sensitive detection of UA in the range from 0.5 μM to 180 μM with a low limit of detection (LOD, 129 nM, S/N = 3). Owing to good anti-fouling ability and high selectivity of the sensor, direct and rapid detection of UA in human whole blood is realized with very low sample consumption (50 μL).

31 March 2022 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
JGJie Gu
Jie Gu
LJLiu Jun
Liu Jun
YHYang Hong
Yang Hong
YFYi Feng
Yi Feng
XHXiaobo Huang
Xiaobo Huang
Background: Urosepsis is an infectious complication after percutaneous nephrolithotomy (PCNL). This study aimed to analyze the perioperative factors related to urosepsis after PCNL for upper urinary calculi and establish a nomogram to predict the probability of postoperative urosepsis based on the risk factors. Methods: The Clinical data of one-stage PCNL for upper urinary stones in patients already diagnosed with type 2 diabetes between June 2010 and June 2020 were retrospectively analyzed. The patients were divided into two groups according to whether urosepsis occurred after surgery, and univariate and multivariate logistic regression analyses evaluated the risk factors for urosepsis. Moreover, the corresponding nomogram prediction model was determined by the regression coefficient. Results: All 366 patients with diabetes underwent one-stage PCNL. Seventy-one (19.4%) patients had urosepsis after surgery, and their hospitalization time was longer than that of patients without urosepsis. Moreover, the incidence of non-infection-related complications was higher. Multivariate logistic regression analysis revealed four independent risk factors associated with postoperative urosepsis, including positive urine nitrite (odds ratio [OR] = 3.326, P = 0.007), positive urine culture (OR = 2.213, P = 0.023), intraoperative hypotension (OR = 8.968, P < 0.001), and staghorn calculi (OR = 3.180, P = 0.002). The above independent risk factors were used as variables to construct the nomogram. The nomogram model was internally validated. The calculated concordance index was 0.824. The Hosmer–Lemeshow goodness-of-fit test was performed (P = 0.972 > 0.05). The area under the curve of this model was 0.831, indicating that the nomogram model had good accuracy in predicting the probability of urosepsis in patients who underwent PCNL with diabetes and had good consistency with the actual risk. Conclusion: Positive urine culture, positive urine nitrite, staghorn calculi, and intraoperative hypotension were independent risk factors for urosepsis in patients who underwent one-stage PCNL with diabetes. The new nomogram could accurately assess the risk of urosepsis after PCNL in patients with diabetes.

16 November 2022 in BMC Surgery
Verified
Journal Article
Open access
PDF file
LJLiu Jun
Liu Jun
JGJie Gu
Jie Gu
WXWenkuan Xu
Wenkuan Xu
CTCong Tian
Cong Tian
DPDong Pang
Dong Pang
XHXiaobo Huang
Xiaobo Huang
Background: Percutaneous nephrolithotripsy (PCNL) is difficult to perform for elderly patients; thus, this study aimed to assess its efficacy and safety in elderly patients aged > 70 years, note any associations between outcomes and patient characteristics, and summarize relevant themes and observations. Methods: Data from patients older than 70 years who had undergone PCNL for upper urinary tract calculi between January 2016 and January 2021 was retrospectively analyzed. Risk factors for postoperative complications and residual stones were analyzed using multivariate logistic regression. Results: A total of 116 elderly patients underwent 122 PCNL operations, of which six underwent secondary PCNL operations, and all of which were successfully completed. The average age was 74.6 ± 4.3 years; the average stone size and operation time were 3.5 ± 1.8 (1.2–11 cm), and 71.8 ± 34.1 min, respectively. Of the participants, 16 or 13.8% had postoperative complications and 29 (25%) had residual stones after operation. The stone free rate was 75%. Multivariate analysis revealed that an American Score of Anesthesiology III was an independent risk factor for postoperative complications (odds ratio [OR] = 4.453, p = 0.031), and staghorn calculi were independent risk factors for postoperative residual calculi (OR = 31.393, p = 0.001). Conclusion: PCNL was shown to be safe and effective for elderly patients aged > 70 years. Further, ASA III was an independent risk factor for postoperative complications, and staghorn calculi were independent risk factors for postoperative residual calculi in elderly patients.

1 February 2025 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
CSChangxiang Shu
Changxiang Shu
LJLiu Jun
Liu Jun
Background and Objective: As one of the effective minimally invasive methods for upper urinary tract stone treatment, ureteroscopic lithotripsy has gradually become the mainstream surgical approach. The routine use of ureteral access sheaths (UAS) during ureteroscopic lithotripsy has plenty of advantages. Although many concerns have emerged in the clinical practice of the UAS, the clinically improved devices have addressed these issues. This article reviews the advantages, existing issues, and current improvements of UAS in clinical practice, aiming to provide references for better clinical application and further improvements of UAS. Methods: We searched in PubMed database using the terms: “ureteral access sheath”, “ureteroscopic lithotripsy” or “flexible ureteroscope”. Articles were independently evaluated for inclusion based on predetermined criteria. Key Content and Findings: The routine use of UAS during ureteroscopic lithotripsy facilitates the entry and exit of the ureteroscope, improves intraoperative visibility, and reduces postoperative complications. However, concerns over ureteral wall injury, difficulty in controlling renal pelvic pressure, lack of reduction in operation time, failure to increase stone free rates, and controversies regarding the ratios of endoscope-sheath diameter have limited the clinical application of UAS. The emergence of clinically improved devices such as intelligent pressure controlled, tip bendable, and rigid ureteroscope aided UAS has addressed these issues, laying a foundation for their further clinical application. Conclusions: The clinical improvement of the UAS can serve as a bridge for the widespread usage of the ureteroscopic lithotripsy. In the future, we anticipate more innovative advancements in UAS, making their clinical use even more practical and convenient.

5 January 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
LJLiu Jun
Liu Jun
CTCong Tian
Cong Tian
JQJiajia Qiao
Jiajia Qiao
KDKeming Deng
Keming Deng
XYXiongjun Ye
Xiongjun Ye
LXLiulin Xiong
Liulin Xiong
Background: The pivotal roles of long noncoding RNAs (lncRNAs) in the realm of cancer biology, inclusive of bladder cancer (BCa), have been substantiated through various studies. Remarkably, RNA methylation, especially m6A modification, has demonstrated its influence on both coding and noncoding RNAs. Nonetheless, the explicit impact of RNA methylation on lncRNAs and its subsequent contribution to the progression of BCa remains to be elucidated. Methods: In the present investigation, we scrutinized the expression and m6A methylation status of LINC01106, employing quantitative real-time PCR (qRT–PCR) and methylated RNA immunoprecipitation (MeRIP)-qPCR. To decipher the regulatory mechanism underpinning LINC01106, we utilized RNA immunoprecipitation (RIP)-qPCR, methylated RNA immunoprecipitation (MeRIP) assays, and bioinformatic analysis. Furthermore, the CRISPR/dCas13b-METTL3-METTL14 system was implemented to probe the function of LINC01106. Results: The findings of our study indicated that LINC01106 is under expressed and exhibits diminished m6A methylation levels in BCa tissues when compared those of normal controls. A diminished expression of LINC01106 was associated with a less favorable prognosis in BCa patients. Intriguingly, CRISPR-mediated hypermethylation of LINC01106, facilitated by dCas13b-M3-M14, abolished the malignant phenotype of the BCa cells, an effect that could be inverted by Disabled-1 (DAB1) knockdown. From a mechanistic standpoint, we identified an m6A modification site on LINC01106 and highlighted YTHDC1 as a potential reader protein implicated in this process. Additionally, a positive correlation between DAB1 and LINC01106 expression was observed, with miR-3148 potentially acting as a mediator in this relationship. Conclusions: In summary, our research unveils a suppressive regulatory role of the LINC01106/miR-3148/DAB1 axis in the progression of BCa and underscores the YTHDC1-mediated m6A modification mechanism in regards to LINC01106. These revelations propose a new therapeutic target for the management of BCa.

2 September 2024 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
CTCong Tian
Cong Tian
JQJiajia Qiao
Jiajia Qiao
LALizhe An
Lizhe An
YHYang Hong
Yang Hong
QXQingquan Xu
Qingquan Xu
LJLiu Jun
Liu Jun